Zheng Si-Yuan, Zhou Xiao-Qing
Department of Encephalopathy, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Encephalopathy Center, First Clinical Medical School of Henan University of Chinese Medicine, Zhengzhou, China.
Front Neurol. 2025 Jul 4;16:1610542. doi: 10.3389/fneur.2025.1610542. eCollection 2025.
Cognitive impairment (CI) represents a critical public health burden exacerbated by aging populations and inadequate therapeutic options. Conventional treatments usually target single molecules, which limits their effectiveness in addressing the complex pathology of CI. In contrast, herbal medicine provides a systems-level therapeutic approach by simultaneously regulating multiple signaling pathways. This narrative perspective summarizes recent evidence on the pharmacological mechanisms through which herbal therapies mitigate CI. A focused literature review was performed to identify preclinical and clinical studies that emphasize the regulation of key pathways, including PI3K/Akt, Nrf2/HO-1, NF-κB, and BDNF/TrkB. These pathways act synergistically to reduce oxidative damage, inhibit pro-inflammatory cytokine production, and promote neuroplasticity. Representative compounds such as ginsenosides, catalpol, and standardized extracts from and exhibit promising effects on these molecular pathways. Compared with monotherapies, herbal medicines offer a broader pharmacodynamic spectrum and potentially fewer adverse effects. These findings support the integration of herbal medicine into treatment strategies for CI and emphasize the need for high-quality clinical trials and mechanistic studies to validate and optimize its application.
认知障碍(CI)是一个严重的公共卫生负担,老龄化人口和有限的治疗选择使其进一步加剧。传统治疗通常针对单一分子,这限制了它们在解决CI复杂病理方面的有效性。相比之下,草药提供了一种系统层面的治疗方法,可同时调节多个信号通路。本叙述性综述总结了关于草药疗法减轻CI的药理机制的最新证据。进行了一项重点文献综述,以确定强调关键通路(包括PI3K/Akt、Nrf2/HO-1、NF-κB和BDNF/TrkB)调节的临床前和临床研究。这些通路协同作用以减少氧化损伤、抑制促炎细胞因子产生并促进神经可塑性。人参皂苷、梓醇等代表性化合物以及来自[具体植物名称1]和[具体植物名称2]的标准化提取物对这些分子通路表现出有前景的作用。与单一疗法相比,草药具有更广泛的药效学谱且潜在不良反应更少。这些发现支持将草药纳入CI的治疗策略,并强调需要高质量的临床试验和机制研究来验证和优化其应用。